Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
HUTCHMED (China) ( (HK:0013) ) has shared an update.
HUTCHMED (China) Limited has released its 2025 Annual Report along with the Notice of Annual General Meeting and Form of Proxy, making the materials available both in printed form for electing shareholders and online via its corporate website. The company has also scheduled its 2026 Annual General Meeting as a hybrid event on May 12, 2026, combining a physical meeting in Hong Kong with electronic participation, underscoring its efforts to facilitate broader shareholder engagement and transparency in governance processes.
The most recent analyst rating on (HK:0013) stock is a Hold with a HK$23.50 price target. To see the full list of analyst forecasts on HUTCHMED (China) stock, see the HK:0013 Stock Forecast page.
More about HUTCHMED (China)
HUTCHMED (China) Limited is an innovative, commercial-stage biopharmaceutical company focused on discovering, developing and commercializing targeted therapies and immunotherapies for cancer and immunological diseases. The company has advanced multiple in-house discovered drug candidates to market, with three medicines approved in China and one therapy also approved in major global markets including the U.S., Europe and Japan.
Average Trading Volume: 4,707,832
Technical Sentiment Signal: Sell
Current Market Cap: HK$20.29B
For detailed information about 0013 stock, go to TipRanks’ Stock Analysis page.